Provided by Tiger Fintech (Singapore) Pte. Ltd.

Arcutis Biotherapeutics Inc.

14.45
+0.62004.48%
Post-market: 14.790.3400+2.35%18:16 EDT
Volume:1.70M
Turnover:24.79M
Market Cap:1.71B
PE:-12.48
High:15.02
Open:14.35
Low:14.20
Close:13.83
Loading ...

Arcutis Biotherapeutics: Buy Rating Affirmed Amid Positive Long-Term Outlook and Strategic Growth Potential

TIPRANKS
·
Yesterday

Arcutis to Report First Quarter 2025 Financial Results and Host Conference Call on May 6, 2025

GlobeNewswire
·
17 Apr

Arcutis Biotherapeutics Promotes Vairavan to CFO as Topper Plans Retirement

Dow Jones
·
11 Apr

Arcutis Biotherapeutics Names New Chief Financial Officer

MT Newswires Live
·
11 Apr

Arcutis Biotherapeutics CFO David Topper to retire, Latha Vairavan to succeed

TIPRANKS
·
11 Apr

BRIEF-Arcutis Announces Chief Financial Officer Transition

Reuters
·
11 Apr

Arcutis Announces Chief Financial Officer Transition

THOMSON REUTERS
·
11 Apr

Arcutis Biotherapeutics Inc - CFO David Topper to Retire

THOMSON REUTERS
·
11 Apr

Press Release: Arcutis Announces Chief Financial Officer Transition

Dow Jones
·
11 Apr

Arcutis Biotherapeutics Price Target Maintained With a $20.00/Share by Needham

Dow Jones
·
09 Apr

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
05 Apr

Arcutis Biotherapeutics Price Target Maintained With a $20.00/Share by Needham

Dow Jones
·
03 Apr

Strategic Advantage and Market Confidence: Arcutis Biotherapeutics’ Extended Exclusivity and Buy Rating Amidst Competitive Risks

TIPRANKS
·
03 Apr

Why Arcutis Biotherapeutics Inc. (ARQT) Went Up On Wednesday?

Insider Monkey
·
03 Apr

Arcutis Biotherapeutics (ARQT) Receives a Buy from Mizuho Securities

TIPRANKS
·
03 Apr

BRIEF-Arcutis And Padagis Agree To Stay Patent Lawsuit

Reuters
·
03 Apr

BUZZ-Arcutis rises after halting patent dispute with Padagis

Reuters
·
03 Apr

Arcutis Agrees to Stay Patent Lawsuit Against Padagis

MT Newswires Live
·
03 Apr

Arcutis Biotherapeutics: Padagis to Report to Co Any FDA Correspondence About Anda for Their Generic Alternative to Zoryve Cream 0.3%

THOMSON REUTERS
·
03 Apr

Arcutis and Padagis Agree to Stay Patent Lawsuit

THOMSON REUTERS
·
03 Apr